One World Cannabis

Company Overview

Snapshot

Founded in January 2008 by Ziv Turner and Alon Sinai, One World Cannabis operates with 1–10 employees. The company has raised $2 million across two funding rounds and was publicly listed on the OTC exchange in March 2009.

Business overview

One World Cannabis is dedicated to the discovery, development, and commercialization of cannabis-based therapeutic products and treatments. The company focuses on investigating specific cannabis strains, combinations of THC and CBD cannabinoids, and optimal dosages to address various medical conditions. Its initial clinical trials target fibromyalgia, psoriasis, basal cell carcinoma, post-traumatic stress disorder, and seizures, with subsequent trials planned for Crohn's disease, Parkinson's disease, Tourette's syndrome, migraines, chronic pain, Alzheimer's disease, pediatric epilepsy, prostate cancer, and diabetes. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology and Medical Cannabis, One World Cannabis serves both B2B and B2C markets in Israel and the United States.

Strategic signal

In September 2020, One World Cannabis's parent company, OWC Pharmaceutical Research Corp., announced a new distribution agreement with Can It Industries in Florida, US. This agreement signaled an expansion of the company's market reach and distribution capabilities within the United States, indicating a strategic move to broaden access to its cannabis-based products.

Company Intelligence Q&A

What is One World Cannabis's primary focus?

One World Cannabis focuses on discovering, developing, and commercializing cannabis-based therapeutic products and treatments, investigating specific cannabis strains, cannabinoid combinations, and optimal dosages.

When did One World Cannabis become publicly traded?

One World Cannabis became publicly traded on the OTC exchange in March 2009.

What was a significant partnership for OWC Pharmaceutical Research Corp.?

In September 2020, OWC Pharmaceutical Research Corp. announced a new distribution agreement with Can It Industries in Florida, US, to expand its market presence.

What clinical trials did One World Cannabis intend to pursue?

One World Cannabis intended to explore potential treatments for fibromyalgia, psoriasis, basal cell carcinoma, post-traumatic stress disorder, and seizures in its first clinical trials, with subsequent trials for conditions like Crohn's disease and Parkinson's disease.

When was Dr. Oron Yacoby Zeevi appointed Chief Scientific Officer?

OWC Pharmaceutical Research Corp. appointed Dr. Oron Yacoby Zeevi as its Chief Scientific Officer in March 2018.